Stock Events

Stock Events

Crescent Biopharma 

€0
0
+€0+0% Today

Statistics

Day High
-
Day Low
-
52W High
-
52W Low
-
Volume
-
Avg. Volume
-
Mkt Cap
0
P/E Ratio
-
Dividend Yield
-
Dividend
-

Upcoming

Earnings

30AprExpected
Q4 2025
Next
-3.4
-2.51
-1.63
-0.75
Expected EPS
-0.7492453488
Actual EPS
N/A

People Also Follow

This list is based on the watchlists of people on Stock Events who follow C68.STU. It's not an investment recommendation.

Competitors

This list is an analysis based on recent market events. It's not an investment recommendation.
Sangamo Therapeutics
SGMO
Mkt Cap124.32M
Sangamo Therapeutics works on genomic medicines for genetic diseases, potentially competing in the same therapeutic areas as GlycoMimetics.
CRISPR Therapeutics
CRSP
Mkt Cap4.75B
CRISPR Therapeutics is involved in gene editing for genetic diseases, which could compete with GlycoMimetics' drug development programs.
Vertex Pharmaceuticals
VRTX
Mkt Cap111.43B
Vertex Pharmaceuticals develops treatments for cystic fibrosis and other serious diseases, competing in the broader market for rare diseases.
Novartis
NVS
Mkt Cap297.32B
Novartis offers a wide range of pharmaceutical products, including treatments for conditions that GlycoMimetics targets.
Biomarin Pharmaceutical
BMRN
Mkt Cap10.67B
BioMarin Pharmaceutical focuses on enzyme replacement therapies for rare genetic disorders, competing in the rare disease space with GlycoMimetics.
Alnylam Pharmaceuticals
ALNY
Mkt Cap42.29B
Alnylam Pharmaceuticals specializes in RNAi therapeutics for genetic diseases, potentially competing with GlycoMimetics' therapeutic approaches.
Sarepta Therapeutics
SRPT
Mkt Cap2.44B
Sarepta Therapeutics develops RNA-based therapeutics for rare diseases, which could compete with GlycoMimetics' products.
AMGEN
AMGN
Mkt Cap187.56B
Amgen is a biotechnology company with a broad portfolio, including treatments for conditions that GlycoMimetics may target.

About

Crescent Biopharma, Inc., a biotechnology company, researches and develops cancer therapy candidates in the United States. Its pipeline includes CR-001, which is in Phase 3 clinical trial, a proprietary anti-PD-1/anti-VEGF bispecific antibody to treat solid tumors; and CR-002, and CR-003. The company has a strategic partnership with Sichuan Kelun-Biotech Biopharmaceutical Co., Ltd. for the development and commercialization of oncology therapeutics. The company was formerly known as GlycoMimetics, Inc. The company was founded in 2024 and is headquartered in Waltham, Massachusetts.
Show more...
CEO
Mr. Joshua T. Brumm
Employees
44
Country
US
ISIN
KYG2545C1042

Listings

F
DE
C68.F
STU
DE
C68.STU
XNAS
US
CBIO
BOATS
BOATS
CBIO.BOATS

0 Comments

Share your thoughts

FAQ

What is Crescent Biopharma stock ticker?▼
Depending on the exchange, the stock ticker may vary. For instance, on exchange Crescent Biopharma stocks are traded under the ticker C68.STU.
When is the next Crescent Biopharma earnings date?▼
Crescent Biopharma is going to release the next earnings report on April 30, 2026.
What were Crescent Biopharma earnings last quarter?▼
C68.STU earnings for the last quarter are -3.4 EUR per share, whereas the estimation was -2.09 EUR resulting in a -62.25% surprise. The estimated earnings for the next quarter are N/A EUR per share.
How many employees does Crescent Biopharma have?▼
As of April 11, 2026, the company has 44 employees.
When did Crescent Biopharma complete a stock split?▼
Crescent Biopharma has not had any recent stock splits.
Where is Crescent Biopharma headquartered?▼
Crescent Biopharma is headquartered in Waltham, US.